

해외 바이오의약품 임상 현황 ('22년 12월 4주)

한국바이오의약품협회, 2023.01.03.

※ ClinicalTrials.gov에 등록된 국가별 바이오의약품 임상시험 목록(병용요법 포함)을 한국바이오의약품협회에서 주간 업데이트하여 제공합니다.
URL을 클릭하시면 세부 정보 페이지로 연결됩니다.
- 출처: ClinicalTrials.gov
- 모니터링 기간: 2022.12.26. ~ 2023.01.01.
- 주간 업데이트 제공국가 : 미국, 유럽(영국, 프랑스, 독일), 중국, 일본

○ 미국 64건

NCT Number	Title	Interventions	Sponsor/Collaborators	Phases	URL
NCT05664243	A Phase 1b / 2 Drug Resistant Immunotherapy With Activated, Gene Modified Allogeneic or Autologous 欸漚 T Cells (DeltEx) in Combination With Maintenance Temozolomide in Subjects With Recurrent or Newly Diagnosed Glioblastoma	Biological: Autologous genetically modified gamma-delta T cells Biological: Allogeneic genetically modified gamma-delta T cells	In8bio Inc.	Phase 1 Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT05664243
NCT05655819	A Study of Glutamine to Treat Intestinal Permeability in Functional Dyspepsia	Drug: Glutamine Drug: Placebo	David J. Cangemi Mayo Clinic	Phase 1 Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT05655819
NCT05639972	E7 T-cell Receptor (TCR) -T Cell Induction Therapy for Locoregionally Advanced HPV-associated Cancers	Drug: Conditioning, E7 TCR-T cells, and aldesleukin	Rutgers, The State University of New Jersey National Cancer Institute (NCI)	Phase 1 Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT05639972
NCT05626712	Safety and Efficacy of CELZ-201 in Patients With Recent Onset Type 1 Diabetes	Biological: CELZ-201 Administration Other: Control Group	Creative Medical Technology Holdings Inc	Phase 1 Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT05626712
NCT05588453	Natural Killer Cell Therapy (UD TGFbetai NK Cells) and Temozolomide for the Treatment of Stage IV Melanoma Metastatic to the Brain	Biological: Natural Killer Cell Therapy Drug: Temozolomide	Kari Kendra Ohio State University Comprehensive Cancer Center	Phase 1 Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT05588453
NCT05559879	Cabozantinib and Dostarlimab in Recurrent Gynecologic Carcinosarcoma	Drug: Cabo + Dostarlimab	University of Alabama at Birmingham	Phase 1 Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT05559879
NCT04989218	Durvalumab and Tremelimumab With Platinum-based Chemotherapy in Intrahepatic Cholangiocarcinoma (ICC)	Drug: Novel combination of chemotherapy and immunotherapy	University of Alabama at Birmingham	Phase 1 Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT04989218
NCT04691817	Tocilizumab and Atezolizumab in Adults With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Refractory to 1st Line Immune Checkpoint Inhibitor-Based	Drug: Atezolizumab Drug: Tocilizumab	Abramson Cancer Center of the University of Pennsylvania Genentech, Inc.	Phase 1 Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT04691817
NCT04129515	NovoTTF-200A + Pembrolizumab In Melanoma Brain Metastasis	Device: NovoTTF-200A Drug: Pembrolizumab	Brown University NovoCure Ltd.	Phase 1 Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT04129515
NCT04085887	Panitumumab-IRDye800 to Detect Pediatric Neoplasms During Neurosurgical Procedures	Drug: Panitumumab-IRDye800 Device: Pinpoint-IR9000 endoscopic/handheld device Device: Explorer Air camera Device: PDE-NEO-II	Stanford University	Phase 1 Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT04085887
NCT03402789	Docosahexaenoic Acid (DHA) Supplementation in Amblyopia	Drug: Docosahexaenoic Acid Drug: Placebo Oral Tablet	Johns Hopkins University	Phase 1 Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT03402789
NCT02522611	Periganglionic Resiniferatoxin for the Treatment of Intractable Pain Due to Cancer-induced Bone Pain	Drug: Resiniferatoxin	National Institute of Neurological Disorders and Stroke (NINDS) National Institutes of Health Clinical Center (CC)	Phase 1 Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT02522611
NCT05665725	Siltuximab for the Prevention of CAR T Cell Related Cytokine Release Syndrome in Patients With CD19 Positive Non-Hodgkin Lymphoma	Procedure: Biospecimen Collection Procedure: Computed Tomography Procedure: Positron Emission Tomography Biological: Siltuximab	Timothy Voorhees Ohio State University Comprehensive Cancer Center	Phase 1	https://clinicaltrials.gov/ct2/show/study/NCT05665725

해외 바이오의약품 임상 현황 ('22년 12월 4주)

한국바이오의약품협회, 2023.01.03.

NCT05654506	Daratumumab for Treatment of Proliferative Glomerulonephritis With Monoclonal Immune Deposits	Drug: Daratumumab	Mayo Clinic	Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT05654506
NCT05651594	Propranolol in Combination With Pembrolizumab and Standard Chemotherapy for the Treatment of Unresectable Locally Advanced or Metastatic Esophageal or Gastroesophageal Junction Adenocarcinoma	Procedure: Biopsy Procedure: Biospecimen Collection Procedure: Computed Tomography Drug: Fluorouracil Drug: Leucovorin Drug: Oxaliplatin Biological: Pembrolizumab Drug: Propranolol Hydrochloride Other: Questionnaire	Roswell Park Cancer Institute United States Department of Defense	Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT05651594
NCT05650645	The Efficacy of Incobotulinum Toxin A Injections for Treatment of Tinnitus: a Randomized Controlled Trial	Drug: incobotulinum toxin A Drug: Placebo-Saline	University of Minnesota	Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT05650645
NCT05641831	Canakinumab for the Prevention of Progression to Cancer in Patients With Clonal Cytopenias of Unknown Significance, IMPACT Study	Procedure: Biospecimen Collection Procedure: Bone Marrow Aspiration and Biopsy Drug: Canakinumab Procedure: Chest Radiography Procedure: Echocardiography Drug: Placebo Administration Other: Quality-of-Life Assessment	Uma Borate Ohio State University Comprehensive Cancer Center	Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT05641831
NCT05623488	CAR T Cells in Mesothelin-Expressing Breast Cancer	Drug: huCAR-meso cells Device: Mesothelin Expression Testing	University of Pennsylvania	Phase 1	https://clinicaltrials.gov/ct2/show/study/NCT05623488
NCT05609994	ViCToRy: Vorasidenib in Combination With Tumor Specific Peptide Vaccine for Recurrent IDH1 Mutant Lower Grade Gliomas	Drug: PEPIDH1M vaccine + vorasidenib	Katy Peters, MD, PhD Servier Duke University	Phase 1	https://clinicaltrials.gov/ct2/show/study/NCT05609994
NCT05595642	A Study to Evaluate Astegolimab in Participants With Chronic Obstructive Pulmonary Disease	Drug: Astegolimab Drug: Placebo	Hoffmann-La Roche	Phase 3	https://clinicaltrials.gov/ct2/show/study/NCT05595642
NCT05581589	Sacituzumab Govitecan Before Radical Cystectomy for the Treatment of Non-Urothelial Muscle Invasive Bladder Cancer	Procedure: Lymphadenectomy Procedure: Radical Cystectomy Biological: Sacituzumab Govitecan	University of Washington Gilead Sciences	Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT05581589
NCT05537402	LOcoregional vs Systemic Therapy in Patients With BCLC Stage B HCC (LOST- B) Trial	Drug: Atezolizumab and bevacizumab Radiation: transarterial chemoembolization (TACE) or transarterial radioembolization (TARE)	University of Texas Southwestern Medical Center Genentech, Inc.	Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT05537402
NCT05501756	Precision Alemtuzumab Dosing for Allogeneic Hematopoietic Cell Transplantation	Drug: Alemtuzumab	Children's Hospital Medical Center, Cincinnati	Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT05501756
NCT05498220	Polatuzumab Vedotin With R-GDP in Relapsed/Refractory Diffuse Large B-cell Lymphoma	Drug: Polatuzumab vedotin (PV) Drug: Rituximab Drug: Hyaluronidase Drug: Gemcitabine Drug: Cisplatin Drug: Dexamethasone Drug: GCSF	UNC Lineberger Comprehensive Cancer Center Genentech, Inc.	Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT05498220
NCT05496036	Neoadjuvant PD-1 Blockade in Resectable Merkel Cell Carcinoma	Drug: Pembrolizumab	Abramson Cancer Center of the University of Pennsylvania Merck Sharp & Dohme LLC	Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT05496036
NCT05482334	Trial to Evaluate Safety and Efficacy of GM-CSF /Sargramostim in Down Syndrome	Drug: Sargramostim for Injection Drug: Saline Placebo	University of Colorado, Denver National Institute on Aging (NIA)	Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT05482334
NCT05467761	Bioavailability Study of Psilocybin in Normal Adults	Drug: Oral Psilocybin Drug: IV Psilocybin	University of Wisconsin, Madison TRYP Therapeutics	Phase 1	https://clinicaltrials.gov/ct2/show/study/NCT05467761
NCT05464329	Mosunetuzumab in Combination With Platinum-Based Salvage Chemotherapy in Autologous Stem Cell Transplant-Eligible Patients With Relapsed/Refractory Aggressive B Cell	Drug: Mosunetuzumab Drug: DHAX Drug: ICE	Washington University School of Medicine Genentech, Inc.	Phase 1	https://clinicaltrials.gov/ct2/show/study/NCT05464329

해외 바이오의약품 임상 현황 ('22년 12월 4주)

한국바이오의약품협회, 2023.01.03.

NCT05457959	Peptide-Pulsed Dendritic Cell Vaccination in Combination With Nivolumab and Ipilimumab for the Treatment of Recurrent and/or Progressive Diffuse Hemispheric	Biological: Dendritic Cell Tumor Peptide Vaccine Biological: Ipilimumab Procedure: Leukapheresis Biological: Nivolumab Drug: Placebo	Jonsson Comprehensive Cancer Center	Phase 1	https://clinicaltrials.gov/ct2/show/study/NCT05457959
NCT05453500	Chemotherapy (DA-EPOCH+/-R) and Targeted Therapy (Tafasitamab) for the Treatment of Newly-Diagnosed Philadelphia Chromosome Negative B Acute Lymphoblastic Leukemia	Procedure: Bone Marrow Aspiration and Biopsy Drug: Cyclophosphamide Drug: Doxorubicin Drug: Etoposide Drug: Prednisone Biological: Rituximab Biological:	University of Washington Incyte Corporation	Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT05453500
NCT05443971	Durvalumab and Grid Therapy for the Treatment of Non-small Cell Lung Cancer in Patients Who Progressed During or After Treatment With the PACIFIC Regimen	Biological: Durvalumab Radiation: Radiation Therapy	Mayo Clinic National Cancer Institute (NCI)	Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT05443971
NCT05417165	Anti-pneumococcal Vaccine Strategy in Patients With Chronic Lymphocytic Leukemia	Biological: Pneumococcal 13-valent Conjugate Vaccine Biological: Pneumococcal Polyvalent Vaccine	Seema Bhat Ohio State University Comprehensive Cancer Center	Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT05417165
NCT05412290	Mosunetuzumab Consolidation Therapy After autoSCT in r/r Aggressive B Cell Lymphoma	Drug: Mosunetuzumab	Washington University School of Medicine Genentech, Inc.	Phase 1	https://clinicaltrials.gov/ct2/show/study/NCT05412290
NCT05377827	Dose-Escalation and Dose-Expansion Study to Evaluate the Safety and Tolerability of Anti-CD7 Allogeneic CAR T-Cells (WU-CART-007) in Patients With CD7+ Hematologic	Biological: WU-CART-007	Washington University School of Medicine Wugen, Inc.	Phase 1	https://clinicaltrials.gov/ct2/show/study/NCT05377827
NCT05359211	NKTR-255 in Combination With CAR-T Cell Therapy for the Treatment of Relapsed or Refractory Large B-cell Lymphoma	Drug: Cyclophosphamide Drug: Fludarabine Biological: Lisocabtagene Maraleucel Drug: Polymer-conjugated IL-15 Receptor Agonist NKTR-255	Fred Hutchinson Cancer Center Nektar Therapeutics	Phase 1	https://clinicaltrials.gov/ct2/show/study/NCT05359211
NCT05335941	A Phase 2 Study to Evaluate the Triplet Combination of Pemetrexed Plus AB928 (Etrumadenant) + AB122 (Zimberelimab) in Patients With Previously Treated Advanced or Metastatic MTAP Deficient Urothelial	Drug: Pemetrexed Drug: Zimberelimab Drug: Etrumadenant	M.D. Anderson Cancer Center	Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT05335941
NCT05330689	How Does Platelet Dose Impact Clinical Outcomes After PRP Treatment?	Biological: PRP injection dose (<5 billion platelets) Biological: PRP injection dose (between 5 and <10 billion platelets) Biological: PRP injection dose (between 10 and <20 billion platelets) Biological: PRP injection dose (20 billion or greater platelets) Other: Saline injection	Vanderbilt University Medical Center	Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT05330689
NCT05321940	Safety Trial of STING-dependent Activators and Stimulated Dendritic Cells for Aggressive Relapsed/Refractory Leukemias	Biological: STING-Dependent Activators (STAVs) Loaded Autologous Leukemic Cells Biological: Dendritic Cell Vaccine	Juan C. Ramos, MD University of Miami	Phase 1	https://clinicaltrials.gov/ct2/show/study/NCT05321940
NCT05260957	CAR-T Cell Therapy, Mosunetuzumab and Polatuzumab for Treatment of Refractory/Relapsed Aggressive Non-Hodgkin's Lymphoma (NHL).	Drug: Mosunetuzumab Drug: Polatuzumab Biological: CAR-T Cell Therapy	Lazaros Lekakis Genentech, Inc. University of Miami	Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT05260957
NCT05242965	A Multiple Antigen Vaccine (STEMVAC) for the Treatment of Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer	Biological: CD105/Yb-1/SOX2/CDH3/MDM2-polyepitope Plasmid DNA Vaccine Biological: Sargramostim	University of Washington United States Department of Defense	Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT05242965
NCT05161533	Hypofractionated Radiation Therapy After Durvalumab and Chemotherapy for the Treatment of Stage IV Extensive Stage Small Cell Lung Cancer, CASPIAN-RT Trial	Drug: Carboplatin Drug: Cisplatin Biological: Durvalumab Drug: Etoposide Radiation: Hypofractionated Radiation Therapy Other: Quality-of-Life Assessment Other: Questionnaire Administration	University of Washington AstraZeneca	Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT05161533
NCT05148000	Assess Aesthetic Improvement With QM1114-DP in Subjects With Moderate to Severe Lateral Canthal Lines and Glabellar Lines	Biological: QM1114-DP	Galderma R&D	Phase 3	https://clinicaltrials.gov/ct2/show/study/NCT05148000

해외 바이오의약품 임상 현황 ('22년 12월 4주)

한국바이오의약품협회, 2023.01.03.

NCT05101213	Study Assessing the Feasibility, Safety and Efficacy of Genetically Engineered Glucocorticoid Receptor Knock Out Virus Specific CTL Lines for Multiple Myeloma	Biological: Virus-specific Cytotoxic T-lymphocytes	M.D. Anderson Cancer Center National Cancer Institute (NCI)	Phase 1	https://clinicaltrials.gov/ct2/show/study/NCT05101213
NCT05087342	Latino Semaglutide Study	Drug: Semaglutide 2.4mg Drug: Placebo	Loma Linda University Novo Nordisk A/S	Phase 3	https://clinicaltrials.gov/ct2/show/study/NCT05087342
NCT04876248	Belantamab Mafodotin and Lenalidomide for the Treatment of Multiple Myeloma in Patients With Minimal Residual Disease Positive for CD138+ Cells	Biological: Belantamab Mafodotin Drug: Lenalidomide	Roswell Park Cancer Institute GlaxoSmithKline	Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT04876248
NCT04799431	Neoantigen-Targeted Vaccine Combined With Anti-PD-1 Antibody for Patients With Stage IV MMR-p Colon and Pancreatic Ductal Cancer	Drug: Neoantigen Vaccine with Poly-ICLC adjuvant Drug: Retifanlimab	Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Incyte Corporation National Cancer Institute	Phase 1	https://clinicaltrials.gov/ct2/show/study/NCT04799431
NCT04796012	Atezolizumab in Combination With Chemotherapy for Pediatric Relapsed/Refractory Solid Tumors	Drug: Atezolizumab Drug: Vincristine Drug: Irinotecan Drug: Temozolomide	University of Texas Southwestern Medical Center	Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT04796012
NCT04354025	Cytokine-induced Memory-like NK Cells in Combination With Chemotherapy in Pediatric Patients With Refractory or Relapsed AML	Biological: Cytokine induced memory-like NK cells Drug: Fludarabine Drug: Ara-C Drug: G-CSF Drug: Interleukin-2 Procedure: Leukapheresis	Washington University School of Medicine	Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT04354025
NCT03913117	Study of Treatment for HPV16+ ASC-US or LSIL	Biological: pNGVL4aCRTE6E7L2 Biological: TA-CIN	University of Alabama at Birmingham Johns Hopkins University	Phase 1	https://clinicaltrials.gov/ct2/show/study/NCT03913117
NCT05656235	Renal Retention in High Grade Upper Tract Urothelial Cancer	Drug: Enfortumab vedotin Drug: Pembrolizumab	Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Astellas Pharma Inc Seagen Inc Medigene	Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT05656235
NCT05616221	Study to Evaluate the Safety, Phase Kinetics, and Efficacy of Inhaled AP-PA02 in Subjects With Non-Cystic Fibrosis Bronchiectasis and Chronic Pulmonary Pseudomonas Aeruginosa	Biological: AP-PA02 Other: Placebo	Armata Pharmaceuticals, Inc.	Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT05616221
NCT05244473	A Safety Study of Brentuximab Vedotin in Participants With HIV	Drug: brentuximab vedotin Drug: Placebo Drug: ART	Seagen Inc.	Phase 1	https://clinicaltrials.gov/ct2/show/study/NCT05244473
NCT04952584	Allogeneic CD30 Chimeric Antigen Receptor Epstein-Barr Virus-Specific T Lymphocytes in Relapsed or Refractory CD30-Positive Lymphomas	Biological: CD30.CAR-EBVST cells	Baylor College of Medicine The Methodist Hospital Research Institute	Phase 1	https://clinicaltrials.gov/ct2/show/study/NCT04952584
NCT05067257	Study to Assess Epidural Resiniferatoxin for the Treatment of Intractable Pain Associated With Advanced Cancer	Drug: Resiniferatoxin Drug: Placebo	Sorrento Therapeutics, Inc.	Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT05067257
NCT05007418	Study to Assess Allogeneic Anti-CD38 A2 Dimeric Antigen Receptor T Cells in Relapsed or Refractory Multiple Myeloma	Biological: STI-1492	Sorrento Therapeutics, Inc.	Phase 1	https://clinicaltrials.gov/ct2/show/study/NCT05007418
NCT05567835	A Study of Total Neoadjuvant Chemotherapy With FLOT VS Standard Perioperative FLOT in Patients With Gastric or GEJ Cancer	Drug: Fluorouracil Drug: Leucovorin Drug: Oxaliplatin Drug: Docetaxel Biological: GSCF	Baylor College of Medicine	Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT05567835
NCT05545072	Add-on Dupilumab for AFRS as Postoperative Therapy (ADAPT)	Drug: Dupilumab 300 MG/2 ML Subcutaneous Solution Drug: Placebo	Emory University Sanofi	Phase 3	https://clinicaltrials.gov/ct2/show/study/NCT05545072
NCT05537233	ADJUnct Semaglutide Treatment in Type 1 Diabetes	Drug: Semaglutide Drug: Placebo	University of Colorado, Denver Juvenile Diabetes Research Foundation	Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT05537233
NCT04803006	A Study of TCD601 in the Induction of Tolerance in de Novo Renal Transplantation (PANORAMA)	Biological: TCD601	ITB-Med LLC	Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT04803006

해외 바이오의약품 임상 현황 ('22년 12월 4주)

한국바이오의약품협회, 2023.01.03.

NCT05574335	Siplizumab in T1DM	Drug: Siplizumab	National Institute of Allergy and Infectious Diseases (NIAID)	Phase 1 Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT05574335
NCT05484622	Study of Vorasidenib and Pembrolizumab Combination in Recurrent or Progressive Enhancing IDH-1 Mutant Astrocytomas	Drug: Vorasidenib Drug: Pembrolizumab	Institut de Recherches Internationales Servier Merck Sharp & Dohme LLC Servier	Phase 1	https://clinicaltrials.gov/ct2/show/study/NCT05484622
NCT05063565	TheraSphere With and Without Durvalumab and Tremelimumab for HCC	Device: TheraSphere Y-90 glass microsphere therapy Drug: Durvalumab (Imfinzi) immunotherapy Drug: Tremelimumab	Boston Scientific Corporation Biocompatibles UK Ltd	Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT05063565
NCT05383170	A Study to Evaluate the Safety and Efficacy of CyPep-1 in Combination With Pembrolizumab for the Treatment of Advanced or Metastatic Cancers	Drug: CyPep-1 Drug: Pembrolizumab 25 MG/ML [Keytruda]	Cytovation AS Merck Sharp & Dohme LLC	Phase 1 Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT05383170
NCT04975334	Opioid Antagonism in Hypogonadotropic Hypogonadism	Drug: kisspeptin, GnRH, naloxone Drug: GnRH Drug: Naloxone	Stephanie B. Seminara, MD Massachusetts General Hospital	Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT04975334

○ 영국 3건

NCT Number	Title	Interventions	Sponsor/Collaborators	Phases	URL
NCT05646199	Semaglutide vs Metformin in Polycystic Ovary Syndrome (PCOS)	Drug: Metformin Drug: Semaglutide Injectable Product	University of Hull	Phase 2 Phase 3	https://clinicaltrials.gov/ct2/show/study/NCT05646199
NCT05661916	A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ALN-TTRSC04 in Healthy Subjects	Drug: ALN-TTRSC04 Drug: Placebo	Alnylam Pharmaceuticals	Phase 1	https://clinicaltrials.gov/ct2/show/study/NCT05661916
NCT05648110	A Study for Immunocompromised Patients for Pre Exposure Prophylaxis of COVID-19 With AZD5156.	Biological: Placebo Biological: AZD5156 Biological: AZD7442 (EVUSHELD)	AstraZeneca	Phase 3	https://clinicaltrials.gov/ct2/show/study/NCT05648110

○ 프랑스 5건

NCT Number	Title	Interventions	Sponsor/Collaborators	Phases	URL
NCT05654753	The Efficacy of Fecal Microbiota Transplantation on Axial Spondyloarthritis Patients Resistant to Conventional Treatment	Drug: active FMT Drug: Placebo	Assistance Publique - Hôpital de Paris Fondation Arthritis & Clarins Worldwide 2016	Phase 2 Phase 3	https://clinicaltrials.gov/ct2/show/study/NCT05654753
NCT05071222	Safety and Efficacy Study of Transplantation of Autologous CD34+ Cells Transduced With the G2ARTE Lentiviral Vector Expressing the DCLRE1C cDNA in Artemis (DCLRE1C) Deficient Severe Combined Immunodeficiency	Genetic: ARTEGENE drug product	Assistance Publique - Hôpital de Paris	Phase 1 Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT05071222
NCT05651607	Evaluation of the Efficacy of CANNABIDIOL on the Pruritus in Children With Hereditary Epidermolysis Bullosa	Drug: Cannabidiol	Assistance Publique - Hôpital de Paris HELEBOR Fondation Apicil Lions Club	Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT05651607
NCT05383170	A Study to Evaluate the Safety and Efficacy of CyPep-1 in Combination With Pembrolizumab for the Treatment of Advanced or Metastatic	Drug: CyPep-1 Drug: Pembrolizumab 25 MG/ML [Keytruda]	Cytovation AS Merck Sharp & Dohme LLC	Phase 1 Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT05383170
NCT05648110	A Study for Immunocompromised Patients for Pre Exposure Prophylaxis of COVID-19 With AZD5156.	Biological: Placebo Biological: AZD5156 Biological: AZD7442 (EVUSHELD)	AstraZeneca	Phase 3	https://clinicaltrials.gov/ct2/show/study/NCT05648110

○ 독일 5건

NCT Number	Title	Interventions	Sponsor/Collaborators	Phases	URL
NCT05583071	Methotrexate, Tafasitamab, Lenalidomide and Rituximab in Patients With PCNSL	Drug: Tafasitamab Drug: Lenalidomide Drug: Rituximab Drug: Methotrexate	University of Cologne Incyte Corporation	Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT05583071
NCT04881682	Immunoadsorption Versus Immunoglobulins for Treatment of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)	Device: Immunoadsorption Biological: Immunoglobulins	University of Ulm Milenyi Biomedicine GmbH	Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT04881682

해외 바이오의약품 임상 현황 ('22년 12월 4주)

한국바이오의약품협회, 2023.01.03.

NCT05528913	Benralizumab in Chronic Prurigo - Investigating Clinical Efficacy (BICPIC)	Drug: Fasenna Prefilled Syringe Other: Matching Placebo Solution	Charite University, Berlin, Germany	Phase 2	https://clinicaltrials.gov/ct2/show/study?term=NCT05528913&rank=1
NCT05665140	Expression-linked and R-ISS-adapted Stratification for First Line Therapy in Multiple Myeloma Patients	Drug: Isatuximab Drug: Lenalidomide Drug: Bortezomib Drug: Dexamethasone Other: autologous stem cell transplant	University Hopsital Schleswig Holstein Campus L체beck	Phase 2 Phase 3	https://clinicaltrials.gov/ct2/show/study?term=NCT05665140&rank=1
NCT05621616	A Study of Mirabegron in Young Children With Neurogenic Detrusor Overactivity	Drug: mirabegron	Astellas Pharma Global Development, Inc. Astellas Pharma Inc	Phase 3	https://clinicaltrials.gov/ct2/show/study?term=NCT05621616&rank=1

○ 중국 28건

NCT Number	Title	Interventions	Sponsor/Collaborators	Phases	URL
NCT03759405	IPS Differentiated Cardiomyocytes Vein Transplantation for Chronic Heart Failure	Biological: iPS differentiated cardiomyocytes	Beijing University of Chinese Medicine Dongzhimen Hospital, Beijing	Phase 2 Phase 3	https://clinicaltrials.gov/ct2/show/study?term=NCT03759405&rank=1
NCT05667155	Clinical Study of Cord Blood-derived CAR NK Cells Targeting CD19/CD70 in Refractory/Relapsed B-cell Non-Hodgkin Lymphoma	Biological: CB dualCAR-NK19/70	Second Affiliated Hospital, School of Medicine, Zhejiang University	Phase 1	https://clinicaltrials.gov/ct2/show/study?term=NCT05667155&rank=1
NCT05663086	Immunogenicity and Safety of COVID-19 Vaccine in Population Aged 18 Years and Above	Biological: One dose group Biological: Two doses group Biological: Aged 18-59 years Biological: Aged 60 years old and above	Guangzhou Patronus Biotech Co., Ltd. Yantai Patronus Biotech Co., Ltd.	Phase 2	https://clinicaltrials.gov/ct2/show/study?term=NCT05663086&rank=1
NCT05659186	PD-1 Inhibitor and Anlotinib Combined With Multimodal Radiotherapy in Recurrent or Metastatic Anaplastic Thyroid Cancer	Drug: Tislelizumab Drug: Anlotinib Radiation: Radiotherapy	West China Hospital	Phase 2	https://clinicaltrials.gov/ct2/show/study?term=NCT05659186&rank=1
NCT05659056	Neoadjuvant Study With Pyrotinib and Trastuzumab and Abraxane in Patients With HER2-enriched Breast Cancer	Drug: Pyrotinib, trastuzumab, abraxane	The First Affiliated Hospital with Nanjing Medical University Jiangsu HengRui Medicine Co., Ltd.	Phase 2	https://clinicaltrials.gov/ct2/show/study?term=NCT05659056&rank=1
NCT05657418	A Clinical Study to Evaluate the Safety and Tolerability of JS107 in Advanced Pancreatic Cancer	Drug: JS107 Combination Product: JS107 combination with Toripalimab	Shanghai Junshi Bioscience Co., Ltd.	Phase 1	https://clinicaltrials.gov/ct2/show/study?term=NCT05657418&rank=1
NCT05656573	CART-PSMA Cells for Advanced Prostate Cancer	Drug: CART-PSMA cells	Nova Therapeutics LLC Chinese PLA General Hospital	Phase 1	https://clinicaltrials.gov/ct2/show/study?term=NCT05656573&rank=1
NCT05650242	A Trial to Evaluate Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of BA1106 in Advanced Solid Tumors	Drug: BA1106	Shandong Boan Biotechnology Co., Ltd	Phase 1	https://clinicaltrials.gov/ct2/show/study?term=NCT05650242&rank=1
NCT05647954	A Study of HX008 Plus Transcatheter Arterial Chemoembolization (TACE) in the First-Line Treatment of Subjects With Stage IV (M1c) Melanoma That is Metastatic to the Liver	Drug: HX008 + TACE Drug: Temozolomide + TACE Drug: Pembrolizumab	Taizhou Hanzhong biomedical co. LTD	Phase 3	https://clinicaltrials.gov/ct2/show/study?term=NCT05647954&rank=1
NCT05645627	A Study to Evaluate IBI112 in the Treatment of Psoriasis With Moderate to Severe Plaque Psoriasis	Drug: IBI112 Drug: placebo /IBI112	Innovent Biologics (Suzhou) Co. Ltd.	Phase 3	https://clinicaltrials.gov/ct2/show/study?term=NCT05645627&rank=1
NCT05638594	Pyrotinib Combined With Trastuzumab, Dapiciclib, Letrozole Versus TcbHP (Trastuzumab Plus Pertuzumab With Docetaxel and Carboplatin) as Neoadjuvant Treatment in HR +/HER2 + Breast	Drug: Pyrotinib Drug: Trastuzumab Drug: Dapiciclib Drug: Letrozole Drug: Pertuzumab Drug: Docetaxel Drug: Carboplatin Drug: Gonadotropin-releasing hormone agonist	Shengjing Hospital	Phase 2	https://clinicaltrials.gov/ct2/show/study?term=NCT05638594&rank=1
NCT05631899	Combination of CAR-DC Vaccine and PD-1 Antibody in Local Advanced/Metastatic Solid Tumors	Biological: KRAS-EphA-2-CAR-DC Drug: Abraxane Drug: Cyclophosphamide Drug: PD-1	Chinese PLA General Hospital Zhejiang University	Phase 1	https://clinicaltrials.gov/ct2/show/study?term=NCT05631899&rank=1
NCT05631886	Combination of CAR-DC Vaccine and PD-1 Antibody in Malignant Tumors	Biological: TP53-EphA-2-CAR-DC Drug: Abraxane Drug: Cyclophosphamide Drug: PD-1	Chinese PLA General Hospital Zhejiang University	Phase 1	https://clinicaltrials.gov/ct2/show/study?term=NCT05631886&rank=1
NCT05596708	Phase III Study of Telitacicept in Patients With IgA Nephropathy	Drug: Telitacicept Drug: Placebo	Second Affiliated Hospital, School of Medicine, Zhejiang University	Phase 3	https://clinicaltrials.gov/ct2/show/study?term=NCT05596708&rank=1

해외 바이오의약품 임상 현황 ('22년 12월 4주)

한국바이오의약품협회, 2023.01.03.

NCT05586100	Neoadjuvant and Adjuvant Toripalimab and Cetuximab in Patients With Recurrent, Resectable Squamous Cell Carcinoma of Head and Neck: a Prospective, Single-	Drug: Toripalimab+cetuximab	Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University	Phase 2	http://clinicaltrials.gov/ct2/show/study?term=NCT05586100&rank=1
NCT05513573	Phase II Clinical Study to Compare the Efficacy and Safety of HLX07 + Serplulimab +Chemotherapy Versus Placebo + Serplulimab + Chemotherapy in First-Line Treatment of Patients With Recurrent or Metastatic NPC	Drug: HLX07 Drug: HLX10 Drug: placebo Drug: chemotherapy	Shanghai Henlius Biotech	Phase 2	http://clinicaltrials.gov/ct2/show/study?term=NCT05513573&rank=1
NCT05505461	Neoadjuvant Immunotherapy and Chemoradiotherapy for Locally Advanced Esophagogastric Junction Adenocarcinoma	Drug: neoadjuvant Radiation plus SOX and PD-1 antibody	Peking University People's Hospital	Phase 2	http://clinicaltrials.gov/ct2/show/study?term=NCT05505461&rank=1
NCT05348811	HAIC Combined With Donafenib and Sintilimab for Unresectable ICC	Drug: HAIC combined with donafenib and sintilimab	Zhongda Hospital	Phase 2	http://clinicaltrials.gov/ct2/show/study?term=NCT05348811&rank=1
NCT05338580	Clinical Trial of TJ271 Injection Combined With Pembrolizumab in the Treatment of Advanced Solid T	Drug: TJ271 Injection in Combination with Pembrolizumab	I-Mab Biopharma Co. Ltd.	Phase 2	http://clinicaltrials.gov/ct2/show/study?term=NCT05338580&rank=1
NCT05259540	Effect of Compound Kushen Injection Combined With Pabolizumab in the Treatment of Cervical Adenocarcinoma	Drug: compound kushen injection combined with pabolizumab	Women's Hospital School Of Medicine Zhejiang University	Phase 2	http://clinicaltrials.gov/ct2/show/study?term=NCT05259540&rank=1
NCT05044871	Biomarker-driven Targeted Therapy in Patients With Recurrent Platinum-resistant Epithelial Ovarian Cancer	Drug: Pamiparib Drug: Bevacizumab Drug: Tislelizumab Drug: Nab paclitaxel Drug: Bevacizumab + Nab paclitaxel (intense dose-dense)	Tongji Hospital Qilu Hospital of Shandong University Hubei Cancer Hospital Hunan Cancer Hospital Peking University Cancer Hospital & Institute Obstetrics and Gynecology Hospital of Zhejiang University Sun Yat-sen University Anhui Provincial Cancer	Phase 2	http://clinicaltrials.gov/ct2/show/study?term=NCT05044871&rank=1
NCT04947033	A Study Evaluating TJ210001 in the Treatment of Subjects With Advanced Solid Tumors	Drug: TJ210001 Injection	I-Mab Biopharma Co. Ltd.	Phase 1	http://clinicaltrials.gov/ct2/show/study?term=NCT04947033&rank=1
NCT05646758	A Clinical Trial of TQB2934 for Injection in Multiple Myeloma Subjects	Drug: TQB2934 injection	Chia Tai Tianqing Pharmaceutical Group Co., Ltd.	Phase 1	http://clinicaltrials.gov/ct2/show/study?term=NCT05646758&rank=1
NCT05608447	Effect of Intensive FMT on Primary Hypertension	Biological: FMT capsules Other: Placebo capsules	Chinese Academy of Medical Sciences, Fuwai Hospital	Phase 1	http://clinicaltrials.gov/ct2/show/study?term=NCT05608447&rank=1
NCT05374603	Savolitinib Combine With Durvalumab in EGFR Wild-type Locally Advanced or Metastatic NSCLC	Drug: Savolitinib Drug: Durvalumab	AstraZeneca	Phase 2	http://clinicaltrials.gov/ct2/show/study?term=NCT05374603&rank=1
NCT05664750	Study to Compare the Efficacy and Safety of Passive Immunization With TNM002 Injection and Human Tetanus Immunoglobulin as Prophylaxis Against Tetanus	Drug: TNM002 Drug: Human tetanus immunoglobulin (HTIG)	Trinomab Biotech Co., Ltd.	Phase 3	http://clinicaltrials.gov/ct2/show/study?term=NCT05664750&rank=1
NCT05587374	Cadonilimab (PD-1/CTLA-4 Bi-specific Antibody) and Chemoradiotherapy in Locoregionally-advanced Nasopharyngeal Carcinoma	Drug: Cadonilimab Drug: Gemcitabine Drug: Cisplatin Radiation: Intensity-modulated radiotherapy	Sun Yat-sen University Akeso Pharmaceuticals, Inc.	Phase 3	http://clinicaltrials.gov/ct2/show/study?term=NCT05587374&rank=1
NCT05046314	A Clinical Study of TK216 in Patients With Relapsed or Refractory Ewing's Sarcoma	Biological: TK216+Vincristin	Shanghai Pharmaceuticals Holding Co., Ltd	Phase 2	http://clinicaltrials.gov/ct2/show/study?term=NCT05046314&rank=1